We first confirmed that recombinant human TGF-β treatment induces activation of the canonical TGF-β/SMAD pathway in seven HNSCC cell lines, that is, SAS, HSC2, HSC3, HSC4, Ca9-22, KUMA1, and Gun-1 cells. This evidence concerns the gene TGFB1 and head and neck squamous cell carcinoma.